Journal Report

MOLECULAR CANCER THERAPEUTICS

Download PDF
Journal Information
Journal Title
MOLECULAR CANCER THERAPEUTICS
Publisher
AMER ASSOC CANCER RESEARCH
ISSN
1535-7163
E-ISSN
1538-8514
Database
Clarivate
Domain
Health Sciences, Life Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Preclinical modeling of trastuzumab deruxtecan in a mouse model of brain metastatic triple-negative breast cancer identifies two contributors to efficacy.
Imran Khan, Dinesh Kumar, Simone Difilippantonio et al.
2026-10-24
DOI: 10.1158/1535-7163.mct-26-0592
Inhibition of PLK1 Helps Restrict c-Met–Induced Growth and Therapeutic Resistance of Renal Cancer Cells
Laxminarayan Rawat, Chiranth M. Prakash, Yuzuru Sasamoto et al.
2026-10-16 Pages OF1-OF14
DOI: 10.1158/1535-7163.mct-26-0483
Combined ATR and mitotic inhibition is effective against MYCN-amplified neuroblastoma
Katarzyna Radke, Karin Hansson, Subhayan Chattopadhyay et al.
2026-10-15
DOI: 10.1158/1535-7163.mct-26-0270
Targeting Pancreatic Cancer with Adenoviral Vectors Equipped with Transgenes
Brett L. Roach, Mizuho Sato-Dahlman, Kari Jacobsen et al.
2026-10-14 Pages OF1-OF13
DOI: 10.1158/1535-7163.mct-25-1231
Targeting YAP/TEAD signaling disturbs RNA Pol II activity and enhances immunotherapy response via activated cytosolic DNA sensing pathway in gastroesophageal cancer
Yan-ting Yann. Zhang, Ayna Mammedova, Dipti Athavale et al.
2026-10-8
DOI: 10.1158/1535-7163.mct-25-1491
PLK1 inhibition by onvansertib enhances paclitaxel efficacy and overcomes resistance in HR+/HER2- breast cancer refractory to endocrine therapy and CDK4/6 inhibitors
Sreeja Sreekumar, Migdalia E. Gonzalez, Davis Klein et al.
2026-10-8
DOI: 10.1158/1535-7163.mct-26-0239
Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids
Thomas S. Dexheimer, Zahra Davoudi, Nathan P. Coussens et al.
2026-10-7
DOI: 10.1158/1535-7163.mct-26-0200
GNTbm-38, a Novel Epigenetic Modulator, Performs Immune Activation and Reprogramming of the Tumor Microenvironment
Chia-Nan Chen, Cheng-Han Chou, Yi-Hong Wu et al.
2026-10-7
DOI: 10.1158/1535-7163.mct-25-1441
Preclinical Characterization of ADCT-241, an Exatecan-Based Antibody–Drug Conjugate Against PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Asma Jabeen, Ben Leatherdale, Rebecca Martin et al.
2026-10-7
DOI: 10.1158/1535-7163.mct-25-1241
Targeting Compensatory AKT Activation Overcomes Resistance to AXL Inhibition in Acute Lymphoblastic Leukemia
Haihong Gao, Yi Zhan, Miao Bao et al.
2026-10-6 Pages OF1-OF15
DOI: 10.1158/1535-7163.mct-26-0020
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: October 28, 2026 09:40